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Edited by Lev KisselevAbstract Nitric oxide synthase (NOS)2, an inducible enzyme
that produces NO during inﬂammation, is transcriptionally reg-
ulated. Our goal was to determine whether high mobility group
(HMG)A1 contributes to human (h)NOS2 gene regulation.
Using a small molecule inhibitor of HMGA1 binding to DNA,
or a dominant-negative form of HMGA1, we blunted the induc-
tion of hNOS2 by pro-inﬂammatory stimuli. Binding of
HMGA1 in the region 3506 to 3375 of the hNOS2 promoter,
a region not previously known to be involved in hNOS2 regula-
tion, contributed to the induction of hNOS2 promoter in con-
junction with upstream enhancer regions. We demonstrate a
previously unknown role for HMGA1 in the regulation of
hNOS2.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pro-inﬂammatory cytokine1. Introduction
Nitric oxide (NO) is a free radical gas that is produced by a
family of NO synthases (NOS) [1]. During inﬂammatory dis-
ease processes, including sepsis, NO is produced via the induc-
ible NOS2 pathway [2]. The molecular mechanisms of NOS2
gene regulation are complex, and occur predominantly at the
level of gene transcription. NOS2 gene regulation was ﬁrst
characterized in murine cells [3,4], and NO production is strik-
ing in rodents, particularly when assessing the eﬀects of lipo-
polysaccharide (LPS) and pro-inﬂammatory cytokines [5].Abbreviations: NO, nitric oxide; NOS, nitric oxide synthase; HMG,
high mobility group; dn, dominant-negative; AP, activator protein;
NF, nuclear factor; LPS, lipopolysaccharide; IL, interleukin; IFN,
interferon; TNF, tumor necrosis factor; IRF, interferon regulatory
factor; Stat, signal transducer and activator of transcription; CM,
cytokine mixture; Dist, Distamycin; bp, base pairs
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doi:10.1016/j.febslet.2008.02.008NO production is increased in human sepsis [6], and a combi-
nation of LPS and pro-inﬂammatory cytokines or exposure to
infectious agents [7] is eﬀective in generating NO in human cul-
tured cells.
While the exact sequences of the upstream cytokine-respon-
sive elements of the murine and human NOS2 promoters are
not conserved, an analogous pattern of cytokine induction of
transcription factor binding has been demonstrated in the
two promoters. It is well described that LPS or interleukin
(IL)-1b induces nuclear factor (NF)-jB binding, and inter-
feron (IFN)-c induces IFN regulatory factor (IRF)-1 and sig-
nal transducer and activator of transcription (Stat)-1a binding
to the murine NOS2 promoter, resulting in a synergistic induc-
tion of NOS2 in macrophages and vascular smooth muscle
cells treated with LPS or IL-1b plus IFN-c [8–12]. Geller
and colleagues [13,14] have reported that in a similar fashion,
IL-1b or tumor necrosis factor (TNF)-a induces NF-jB bind-
ing (5.5, 5.8, and 6.1 kb) and IFN-c induces Stat-1a bind-
ing (5.2 and 5.8 kb) to the human NOS2 promoter, which
may facilitate synergistic induction of the human NOS2 pro-
moter by a cytokine mixture (CM) in human lung epithelial
cells. Recently, it has also been demonstrated that 5 and
6 kb promoter regions act as a classical transcriptional en-
hancer, and evidence was provided for in vivo binding of
NF-jB and Stat-1 in these regions under cytokine stimulation
[15]. Others have shown that 5 0-ﬂanking regions contributing
to cytokine responsiveness include activator protein (AP)-1
sites [16,17], with the interaction of c-Fos and Stat-1 in the
5 kb enhancer [18], and a NF-jB site extending out to
8.2 kb [16,17].
Beyond the interaction of trans-acting factors with cis-acting
elements, architectural transcription factors mediate gene tran-
scription by controlling DNA conformation [19,20]. The high
mobility group (HMG) proteins are a family of architectural
proteins that have been recognized to play a role in the regula-
tion of gene transcription, and an important member of this
family is the HMGA1 protein. HMGA1 binds to AT-rich re-
gions in the minor groove of DNA, and HMGA1 facilitates
the assembly of functional nucleoprotein complexes by induc-
ing changes in DNA structure and by recruiting nuclear pro-
teins into enhancer complexes [20–22]. We have previously
demonstrated a role for HMGA1 in regulation of the murine
NOS2 promoter [23,24], yet the role of HMGA1 in human
NOS2 expression under inﬂammatory conditions is not known.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Dist A blunts induction of hNOS2 mRNA and promoter
activity by CM. (A) A549 cells were treated with CM or PBS, in the
presence of increasing doses of Dist A (lM) or vehicle solution (25%
DMSO). Total RNA was extracted, and Northern blot analyses were
performed using 32P labeled hNOS2 and 18S rRNA probes. This
experiment was performed 2 independent times. (B) Luciferase
reporter plasmid hNOS2 8296 (500 ng/well) was transiently co-
transfected along with b-galactosidase expression plasmid (500 ng/
well) into A549 cells. After transfection, cells were treated with CM or
PBS, in the presence or absence of increasing doses of Dist A (lM) or
vehicle solution (25% DMSO). Cells were harvested for luciferase
activity normalized for b-galactosidase, and plotted as fold induction
of hNOS2 promoter activity from cells receiving no CM and no Dist
A. n = 6 in each group. *P < 0.05 versus vehicle alone group and NS,
not signiﬁcant.2. Materials and methods
2.1. Cell culture and reagents
The human type II alveolar epithelial (A549) cell line (American
Type Culture Collection) was cultured, as described [25]. LPS from
Escherichia coli (LPS, serotype O26:B6) and Distamycin A (Dist A)
were purchased from Sigma. Human IFN-c and IL-1b were purchased
from PeproTech.
2.2. RNA isolation and Northern blot analysis
Cells were initially grown in medium containing 10% fetal bovine ser-
um (FBS), and then changed to 0.4% FBS for 48 h prior to stimulation.
Dist A (0–40 lM) was administered to A549 cells 30 min prior to a CM
of LPS (2 lg/ml), IFN-c (100 U/ml), and IL-1b (10 ng/ml). Vehicle for
CM was phosphate buﬀered saline (PBS), while Dist A was dissolved in
25% dimethyl sulfoxide (DMSO) solution. In the experiments using
CM or Dist A, an appropriate control using the same amount of vehicle
was included. RNA was extracted 12 h later, using the RNeasy mini
RNA isolation kit (Qiagen). Northern blot analysis, using a radiola-
beled hNOS2 probe (provided by Dr. Stella Kourembanas, Boston,
MA), was performed as previously described [23].
2.3. Plasmid constructs and mutagenesis of the human NOS2 promoter
The human dominant-negative (dn) HMGA1 cDNA construct
(mutant HMGI(mII,mIII)) lacks the ability to bind AT-rich DNA
sequences in vitro but retains its ability for speciﬁc protein–protein
interactions with other transcription factors [26]. This mutant con-
struct (provided by Dr. Raymond Reeves, Pullman, WA) was sub-
cloned into the HindIII/KpnI sites of the pCMVFlag expression
vector (Sigma) with optimization of the Kozak consensus sequence,
resulting in generation of the ﬁnal dnHMGA1 plasmid construct.
The hNOS2 luciferase reporter plasmid (8296/+168) in the pGL3-Ba-
sic vector (Promega) was kindly provided by Dr. Joel Moss, Bethesda,
MD. Deletion constructs 5496/+168, 3658/+168, and 2950/+168
were generated by a PCR method using Pfu Turbo polymerase (Strat-
agene) followed by KpnI digestion, using plasmid 8296/+168 as a
template. Also, site-directed mutagenesis of plasmid 8296/+168 was
performed using Pfu polymerase to create an internal deletion of base
pairs (bp) 3658 to 3094 (D3658/3094), bp 3506 to 3375
(D3506/3375), and bp 3348 to 3119 (D3348/3119). All con-
structs were conﬁrmed by sequencing.
2.4. Transient transfection assays
The hNOS2 reporter-promoter constructs (WT and mutant con-
structs, 500 ng/well) and dnHMGA1 expression plasmid or empty vec-
tor (500 ng/well) were transiently transfected into A549 cells using
FuGENE 6 transfection reagent (Roche Applied Science), as described
previously [25]. Twelve hours following transfection of hNOS2 and
dnHMGA1 constructs, cells were changed to medium with 0.4%
FBS and treated with CM. In experiments using Dist A, 8296 con-
struct was transiently transfected into A549 cells, and Dist A (10–
40 lM) or vehicle equivalent was administered 30 min prior to a
CM. b-Galactosidase expression vector was co-transfected with
hNOS2 reporter-promoter constructs (500 ng/well), to normalize for
luciferase activity. In transient transfection experiments, cells were har-
vested 6 h following CM treatment and assayed for luciferase (Prome-
ga luciferase assay system) [25].
2.5. Protein-DNA binding assays
Electrophoretic mobility shift assays were performed as described
[24], using a series of 32P labeled double-stranded oligonucleotide
probes encoding AT-rich regions in the hNOS2 promoter (between
bp 3658 and 2944) and a 43-amino acid synthetic peptide (Peptide
Synthesis Core Facility, Tufts University, Boston, MA) encompassing
the second and third DNA-binding regions of the HMGA1 protein
(MEVPTPKRPRGRPKGSKNKGAAKTRKTTTTPGRKPRGRPK-
KLE, termed HMGA1(2/3)), as described previously [27]. Binding
reactions were run on a 6% polyacrylamide gel, and 500 ng of peptide
was used per binding reaction.3. Results
We administered the minor groove binding drug Dist A to
human alveolar epithelial cells (A549) in the presence or ab-
sence of CM. Dist A is a small molecule that interferes with
binding of HMGA1 to AT-rich regions of DNA [28]. Dist A
suppressed induction of hNOS2 message by CM in A549 cells
(Fig. 1A). To conﬁrm this occurred at the level of gene tran-
scription, Dist A was administered to A549 cells after transfec-
tion with the 8296 hNOS2 promoter construct, in the
presence or absence of CM. Dist A suppressed cytokine induc-
ible hNOS2 promoter activity (Fig. 1B), mimicking its eﬀects
on endogenous levels of hNOS2 mRNA (Fig. 1A). Similar to
the Dist A eﬀect, overexpression of dnHMGA1 suppressed
cytokine induction of the hNOS2 promoter (Fig. 2). In addi-
tion, dnHMGA1 suppressed basal hNOS2 promoter activity,
suggesting HMGA1 may play a role under basal and inﬂam-
matory conditions.
In an eﬀort to uncover the hNOS2 promoter region(s)
responsible for this HMGA1 eﬀect, we co-transfected the
dnHMGA1 expression plasmid with various deletion con-
structs of the hNOS2 promoter, in the presence or absence
of CM. Fig. 3 reveals that deletion beyond enhancer regions
(8296 to 5496) responsible for hNOS2 induction led to a
















































Fig. 2. dnHMGA1 suppresses cytokine induction of hNOS2 promoter
activity. Luciferase reporter plasmid hNOS2 8296 (500 ng/well) was
transiently co-transfected with an expression plasmid for dnHMGA1
(500 ng/well) or empty vector into A549 cells. Cells were exposed to
CM or vehicle, and then harvested for luciferase activity. Promoter
activity was plotted as fold induction of hNOS2 promoter activity
from cells receiving no CM and no dnHMGA1. n = 30 in each group.
*Increase (P < 0.05) versus no CM and no dnHMGA1 and decrease































































Fig. 3. Localization of HMGA1-responsive region in the hNOS2
promoter. Luciferase reporter plasmid constructs (hNOS2 8296,
5496, 3658, and 2950) were transiently co-transfected (500 ng/
well) with an expression plasmid for dnHMGA1 (500 ng/well) or
empty vector into A549 cells. Cells were exposed to CM or vehicle, and
then harvested for luciferase activity. Promoter activity was plotted as
fold induction of hNOS2 promoter activity from cells receiving no CM
and no dnHMGA1. n = 6 in each experiment. *Increase (P < 0.05)
versus no CM and no dnHMGA1; decrease (P < 0.05) versus no CM









 3    4
attccaattaaaaattaaaaatacatacatgaatttaatgttacaaa
  5   6
gggagagagaggaccgggaatttaaaagcaggtgtttgtggtggg
    7
acggggacctgtctgaggaaggatacttcagaaggcaagtcctgg
catccacttgctctttgtcaaaagggaaattgttactctctgactccca




     10
aaaagtcaggcccagagagaagtggcttttccaagatcacatggt
    11
aggtcagcagtgaagctgtgcctcgaacctgggacctttcaggcta
aaggaaaccagaacatgccacgcccagatatgccgatatggcat
     12
cctgattatctccagctgaaggcatttgagaaagagcagctagag
13             -2944 
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Fig. 4. HMGA1 binds to the hNOS promoter. The hNOS2 5 0-ﬂanking
sequence between 3658 and 2944 is depicted, with 13 DNA
sequences (underlined and numbered) containing AT-rich regions used
as probes for protein-DNA binding assays. The bottom panels show
protein-DNA binding reactions using these probes after radiolabeling,
in the presence (+) or absence () of synthetic HMGA1 peptide
(HMGA1(2/3), 500 ng). Reaction mixtures of the probes and
HMGA1(2/3) were then subjected to electrophoresis. Potential
HMGA1 binding sites are denoted by bold type. A vertical line in
the right margin designates regions 3506/3375 and 3348/3119,
which are deleted (D) and tested functionally in Fig. 5.
812 R. Takamiya et al. / FEBS Letters 582 (2008) 810–814of hNOS2 promoter activity by dnHMGA1. The ability of
dnHMGA1 to suppress hNOS2 promoter activity (both in
the presence or absence of CM) remained in construct
3658, but was lost when the promoter was deleted down to
construct 2950. These data suggest that the eﬀect of HMGA1
resides in region 3658 to 2950.
To further elucidate which AT-rich regions of the hNOS2
promoter were capable of binding HMGA1, protein-DNA
binding assays were performed using 13 DNA sequences span-ning major AT-rich regions (between 3658 and 2944) as
probes (Fig. 4). HMGA1 bound more to probes 1–6, and less
to probes 7–13. To conﬁrm functionality of these regions, dele-
tion of 3658 to 3094 within the 8296 construct (D3658/
3094) was performed. This construct allowed hNOS2 pro-
moter transactivation by CM, though to a lesser degree than
the wild-type promoter (Fig. 5A). Notably, expression of the
dnHMGA1 plasmid did not suppress promoter activity in con-
struct D3658/3094. Deletion of region 3506 to 3375
(D3506/3375) also completely abolished suppression of
the hNOS2 promoter by dnHMGA1, while deletion of region
3348 to 3119 (D3348/3119) did not alter hNOS2 pro-
moter suppression by dnHMGA1 (Fig. 5B). Together, these
data localize the AT-rich regions from 3506 to 3375 as crit-


























































































































Fig. 5. Deletion of the HMGA1-responsive region suppresses cytokine
induction of the hNOS2 promoter. (A) Luciferase reporter plasmid
hNOS2 8296 and an internal deletion construct from 3658 to
3094 (D3658/3094) were transiently co-transfected (500 ng/well)
with an expression plasmid for dnHMGA1 (500 ng/well) or empty
vector into A549 cells. (B) Internal deletion constructs of hNOS2
8296, from 3506 to 3375 (D3506/3375) and from 3348 to
3119 (D3348/3119), were transiently co-transfected (500 ng/well)
with an expression plasmid for dnHMGA1 (500 ng/well) or empty
vector into A549 cells. Probe regions (from Fig. 4) that were deleted
are noted under the construct names on the x-axis. In both (A) and (B),
cells were exposed to CM or vehicle, and then harvested for luciferase
activity. Promoter activity was plotted as fold induction compared
with hNOS2 8296 receiving no CM and no dnHMGA1. n = 9 in each
group. *Increase (P < 0.05) versus no CM and no dnHMGA1 and
decrease (P < 0.05) versus construct 8296 in the presence of CM and
NS, not signiﬁcant.
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NO is a molecule with a wide variety of functions depending
on the speciﬁc NOS isoform that generates its production, and
how this NOS isoform is being regulated during a physiologic
or pathophysiologic stimulus [7,29]. The inducible isoform,
NOS2, is responsible for upregulation of NO during inﬂamma-
tory processes. We have previously demonstrated the ability of
HMGA1 to facilitate mouse NOS2 promoter activity in vitro
[24], and we also have used a small molecule inhibitor ofHMGA1 binding (Dist A) in mice to blunt NOS2 induction
in vivo and to improve outcome in a model of endotoxemia
[30]. In this report, we advance the understanding of human
NOS2 by determining whether HMGA1 plays a role in its reg-
ulation. Fig. 1 demonstrates that in human lung epithelial cells,
Dist A is able to blunt the induction of hNOS2 at both the le-
vel of mRNA (Fig. 1A) and promoter activity (Fig. 1B). More-
over, by overexpressing a dn form of HMGA1 (dnHMGA1),
we were able to suppress hNOS2 promoter activity (Fig. 2),
both at baseline and after stimulation with a mixture of LPS
and pro-inﬂammatory cytokines (IFN-c and IL-1b), in airway
epithelial cells. These data suggest that HMGA1 plays a role in
the regulation of hNOS2 not only under inﬂammatory condi-
tions, but also at baseline, as human airway epithelial cells are
known to express small amounts of NOS2 under basal condi-
tions [31].
While the major cytokine-responsive elements in the murine
NOS2 promoter are located within 1 kb of the transcription ini-
tiation start site [8,9,11,12], regions of the human NOS2 pro-
moter responsible for maximal cytokine induction are located
much further upstream [13–17]. Interestingly, overexpression
of dnHMGA1 was able to suppress deletion mutants of the
hNOS2 promoter, even when enhancer regions (between
5 kb and 6 kb [15]) responsible for cytokine responsiveness
(Fig. 3) were removed. These data point to a clear separation in
promoter regions responsible for classical cytokine-inducible
enhancer activity and the HMGA1 response. Protein-DNA
binding studies demonstrated that HMGA1 bound at AT-rich
nucleotides spanning region 3658 to 2944 (Fig. 4) of the
hNOS2 promoter, with more binding in region 3506 to
3375. The functional signiﬁcance of this binding was con-
ﬁrmed by the generation of internal deletion constructs, where
deletion of region 3506 to 3375 abolished suppression of
hNOS2 promoter activity by dnHMGA1, either in the presence
or absence of CM (Fig. 5). Moreover, deletion of this region
blunted the cytokine responsiveness of the hNOS2 promoter,
conﬁrming its potential importance. These data support the
concept that binding of HMGA1 at AT-rich sequences in re-
gion 3506 to 3375 of the hNOS2 promoter is important
for full promoter activity, in conjunction with upstream classi-
cal cytokine-inducible enhancer regions [15,16].
This report provides the ﬁrst evidence that HMGA1 is able to
modify the regulation of human NOS2. To our knowledge, the
functional region responsible for HMGA1 activity (3506 to
3375) has never been shown to regulate hNOS2 promoter
activity previously. Thus, our data point toHMGA1 asworking
in conjunction with upstream enhancer regions to most eﬃ-
ciently drive hNOS2 promoter activity. We believe that the un-
ique properties of HMGA1, including the ability to bend and
alter DNA conformation [22], allow widely separated enhancer
regions to interact and regulate human NOS2 expression.
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